sirukumab + prednisone

Sirukumab + prednisone is a **combination therapy** under clinical investigation primarily for the treatment of **giant cell arteritis (GCA)**. Sirukumab is a human IgG1 kappa monoclonal antibody that selectively binds and neutralizes interleukin-6 (IL-6), a cytokine known to be involved in inflammatory pathways critical to GCA pathogenesis. Prednisone is a synthetic glucocorticoid and acts as an immunosuppressant and anti-inflammatory agent, commonly used as first-line therapy in GCA. The combination is tested with the aim to induce and maintain disease remission, reduce glucocorticoid exposure, and decrease the rate of disease relapse and corticosteroid-related adverse effects. The regimen uses sirukumab administered subcutaneously at 100 mg every 2 weeks or 50 mg every 4 weeks, combined with various prednisone tapering schedules[1][2].